Variability in micro RNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to Alzheimer's disease (AD) by Walter J. Lukiw
OPINION ARTICLE
published: 27 August 2013
doi: 10.3389/fncel.2013.00133
Variability in micro RNA (miRNA) abundance, speciation
and complexity amongst different human populations and
potential relevance to Alzheimer’s disease (AD)
Walter J. Lukiw*
Department of Neurology, Neuroscience and Ophthalmology, LSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA
*Correspondence: wlukiw@lsuhsc.edu
Edited by:
Tommaso Pizzorusso, Istituto Neuroscienze CNR, Italy
Reviewed by:
Alessandro Cellerino, Scuola Normale Superiore, Italy
Ferdinando Di Cunto, University of Torino, Italy
Keywords: miRNA profiling, miRNA speciation, Alzheimer’s disease, human populations, caucasian american, african american, superior temporal lobe
neocortex, human biochemical individuality
Toward the end of his 1976 book enti-
tled “Vitamin C and the Common Cold”
Linus Pauling included an interesting
chapter on “human biochemical indi-
viduality” that defined some important
parameters on individual human geno-
typic versus phenotypic variation, based
in part on studies from hemoglobin genet-
ics (Pauling, 1976).That chapter provided
theoretical calculations and novel insight
on genomic diversity, discussing, that
when any genetic characteristic is analyzed
in a sampling of 100 human beings, wide
ranges in values are invariably observed.
The “normalcy” range was defined as that
in which 95% of those “normal values”
lie, while the remaining 5% are described
as “abnormal.” Defining “normalcy” on a
larger scale becomes a bit trickier however,
and Pauling proposed that if we assume
that 500 characters are independently
inherited, then we can calculate that there
is only a small chance, 10%, that one per-
son in the entire global population would
be normal (with respect to each of these
500 characters). If we assume that there are
about 26,600 human genes available to be
expressed in each cell and that each gene
is responsible for at least one inherited
trait or genetic function (a number that
is probably vastly underestimated), in a
global human population exceeding 7 bil-
lion it then becomes exceedingly difficult
to define “human genetic normalcy.” These
ideas form the basis for the evolving con-
cept of “human genetic individuality” and
our ongoing efforts to better understand
the genotypic basis of human phenotypic
diversity in both health and disease (Li
et al., 2010; Raj et al., 2010; Lukiw, 2012a,b;
Olson, 2012; this paper). More recently,
large population studies have analyzed
the contribution of variability in gene
expression, including the impact of genetic
mutations, to “human genetic normalcy,”
“human genetic individuality,” pheno-
type, susceptibility to disease and related
parameters that include the general redun-
dancy in human gene expression that may
directly impact the genetic evolution of
the human species (Colangelo et al., 2002;
Li et al., 2010; Zheng et al., 2011; Lukiw,
2012a,b; Ginsberg et al., 2012; Raj et al.,
2012; Hulse and Cai, 2013). This “Opinion
paper” addresses an observed variability in
micro RNA (miRNA) abundance, specia-
tion and complexity in Alzheimer’s disease
(AD), a common, progressive neurological
disorder unique to the aging human brain
whose incidence is approaching epidemic
proportions (Alzheimer Association,
2013). Here we define miRNA abun-
dance as how much of each individual
miRNA species is present, miRNA speci-
ation as what individual miRNA species
are present, and miRNA complexity as
the pattern of miRNA abundance and
speciation representative of a particular
physiological or pathophysiological state.
One overwhelming observation that
becomes apparent in gene expression
analysis is the vast variability in gene
expression patterns in cells and tissues
derived from different human popu-
lations - these being most noticeable
from Northern-, RT-PCR- and high den-
sity array-based measurements on both
messenger RNA (mRNA) and miRNA
abundance, speciation and complexity in
defined brain anatomical regions from
different human samples. These studies
have been very valuable since the profil-
ing of mRNA and/or miRNA can provide
a powerful “snapshot” into the physiolog-
ical status of a human cell or tissue in
health and disease, and may even be pre-
dictive for the prognosis and/or diagno-
sis for the future outcomes of other AD
patients. Steady-state mRNA and miRNA
levels from different individuals clearly
indicates that the abundance and specia-
tion of these RNAs within clearly defined
anatomical regions can significantly differ
between samples analyzed, suggesting that
genetic variation and extraneous effects,
including age, gender, body mass index
(BMI), apolipoprotein E (ApoE), beta-
amyloid cleavage enzyme (BACE) and
other AD-relevant allele status, life-style
and intrinsic population effects can influ-
ence the profile of mRNAormiRNA abun-
dance and complexity (Colangelo et al.,
2002; Cui et al., 2005; Lukiw, 2007; Lukiw
and Pogue, 2007; Williams et al., 2007;
Sethi and Lukiw, 2009; Ginsberg et al.,
2012). These patterns are further compli-
cated by tissue acquisition and quality con-
trol parameters that include agonal effects,
the analytical approach, and the death-
to-brain freezing interval for post-mortem
human tissues (McLachlan et al., 1989; Cui
et al., 2005; Williams et al., 2007; Sethi
and Lukiw, 2009). Agonal effects include
the circumstances accompanying brain
death, such as whether or not fever (i.e.,
heat shock) was present, whether there
was interceding or accompanying illness
including, commonly, pneumonia or cere-
brovascular disease, and other pathoph-
syiological or interrelated procedural or
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clinical factors (Sethi and Lukiw, 2009; Raj
et al., 2010; Hulse and Cai, 2013).
To illustrate one important example is
the miRNA abundance and speciation of a
small family of inducible, NF-kB-sensitive
miRNAs in two different American
populations—Caucasian Americans and
African Americans afflicted with AD
(Figure 1). A pathogenic quintet of up-
regulated miRNAs have been described
and partially characterized, and these
include miRNA-9, miRNA-34a, miRNA-
125b, miRNA-146a and miRNA-155,
which have been shown to be involved
in chronic inflammatory degeneration
by many independent groups in multiple
human diseases with a progressive inflam-
matory and degenerative component
(Lukiw, 2007; Williams et al., 2007; Wang
et al., 2009; Culpan et al., 2011; Lukiw
et al., 2011; Hu et al., 2012; Iyer et al., 2012;
Saba et al., 2012; Lukiw, 2013; Nussbaum,
2013; Zhao et al., 2013). In AD these
five up-regulated miRNAs appear to play
important roles in the down-regulation of
brain gene expression normally involved in
the brain’s neurotrophic support, synap-
togenesis, the innate-immune response,
NF-kB-mediated inflammatory signaling
and amyloidogenesis (Cui et al., 2005;
Sethi and Lukiw, 2009; Lukiw, 2012a,b;
Zhao et al., 2013). Preliminary data indi-
cates that greater general abundance in
the expression of these five miRNAs
may in part explain differences in the
incidence, course and/or severity of AD
amongst elderly Caucasian American,
African American, Hispanics and other
minority populations. Interestingly, when
comparing AD in human populations,
African Americans and Hispanics appear
to have an increased frequency and sever-
ity of AD when compared to Caucasians,
which may be independent of their APOE
genotype (Tang et al., 1998; Shadlen
et al., 1999; Reitz et al., 2013). The
current results further suggest that in con-
trast to a recent mRNA-based study of
genetic homogeneity in aging humans
(Colantuoni et al., 2011), increased
abundance of pathological miRNAs in
progressive neurodegenerative disorders
may reflect gene expression patterns
highly characteristic of the AD process
in certain human populations. These
results further underscore basic differ-
ences inmiRNA versusmRNA function, in
accordance with their differential modes
of generation, processing and signaling
in development, aging and disease. As
both mRNA and miRNA are intrinsically
unstable molecules with short half-lives,
differential studies using only high qual-
ity, high RIN value, short post-mortem
interval (PMI) mRNA and miRNAmay be
very useful in furthering our understand-
ing of AD epidemiology, and ultimately
also be of use diagnostically and therapeu-
tically in the clinical management of this
common neurological disorder (Espino
and Lewis, 1998; Froehlich et al., 2001;
Cowley et al., 2009; Sethi and Lukiw, 2009;
Venketasubramanian et al., 2010; Lukiw,
2013; Reitz et al., 2013).
Variation in miRNA patterns lends fur-
ther strength to the idea that AD is
not a single, definable neurological dis-
ease entity such as sickle-cell anemia
(Pauling, 1976), but rather a syndrome.
Syndromes are typically a collection of
biomedical symptoms known to fre-
quently appear together, but without a
known or well-defined cause. For exam-
ple, the single point mutation (GAG-
>GTG) in the beta-hemoglobin chain that
changes a glutamate-to-valine, thus gen-
erating mutant hemoglobin causes sickle
cell anemia virtually 100% of the time;
there is no similar single nucleotide change
in any gene product known that asso-
ciates with, or causes AD. Rather, in AD
it appears that multiple interdependent
neurogenetic, neurochemical and neuro-
biological insults progressively accumu-
late and chronically drive oxidative stress,
apoptosis, neuronal cell death, synap-
tic loss and the age-related accumula-
tion of senile plaque and neurofibrillary
tangles, the pathological hall marks of
AD. Obviously neurons can die at differ-
ent rates from diverse pathogenic mecha-
nisms, and different types of neurons have
varied susceptibilities and thresholds to
neurotoxic insults. The recently appreci-
ated contribution of the microbiome to
human systemic physiology may very well
also be involved in homeostasis, health
and diseases including AD (Kostic et al.,
2013). Further, epigenetic and environ-
mental factors such as diet, exercise, stress
and life-style, factors which are known
to impact both AD pathology and gene
expression patterns, are highly variable
amongst different human populations.
Large rigorous population-based studies
involving these multiple risk parameters
still need to be compiled, researched and
analyzed (Williams et al., 2007; Nussbaum,
2013).
Lastly, much independently derived
data comparable to that shown in Figure 1
supports the idea that the genetics and
epigenetics of AD varies widely amongst
different human populations with differ-
ent genetic backgrounds, and these obser-
vations are in accordance with the con-
cept of “human genetic individuality.” If
molecular-genetic and epigenetic profiles
of AD brain samples are any indication of
AD phenotypic variation then there may
be real and significant inter-ethnic differ-
ences in AD epidemiology, incidence, dis-
ease course and progression. This further
suggests that an equally wide variety of
diagnostic and individualistic prevention
and treatment strategies will be required
to more effectively address such progres-
sive, age-related neurological disorders of
the human CNS, including the implemen-
tation of novel combinatorial therapeutic
strategies such as anti-NF-kB and anti-
miRNA approaches that have not yet been
considered (Lukiw, 2013).
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FIGURE 1 | Incidence of miRNA abundance, speciation and complexity
for 5 NF-kB-sensitive pro-inflammatory miRNAs in the superior temporal
lobe (Brodmann Area A22) of 2 different human populations: The current
explosion in miRNA profiling of human disease, including
neuro-degenerative diseases such as Alzheimer’s disease (AD),
underscores “human genetic individuality.” Preliminary data suggests that
there is considerable variation in miRNA abundance, speciation and
complexity in human populations, and variation in miRNA abundance
amongst individuals or populations may be a reflection of their individual
genetic-based susceptibility to disease incidence or severity. (A) depicts a
representative color-coded cluster diagram for 2 control and 2 selected “AD”
populations; control-1 miRNA signals are derived from Caucasian Americans
[age mean ± 1 standard deviation (SD) = 75.5 ± 8.4 year] and control-2
miRNA signals (age mean ± 1 SD = 76.1 ± 7.8 year) are derived from
African Americans; similarly AD-1 miRNA signals are derived from Caucasian
Americans [age mean ±1SD = 77.4 ± 7.5 year] with AD, and AD-2
miRNA signals are derived from African Americans (age mean ± 1
SD = 76.6 ± 8.2year) with AD; all AD cases were for moderate-to-advanced
stages of AD. Because, as single stranded ribonucleotides, miRNAs appear
to have a relatively short half-life, all PMIs had a mean of 2.1 h or less (Sethi
and Lukiw, 2009; Cui et al., 2010); there were no significant differences in
age, PMI, ApoE allele status, RNA quality (all RIN values were 8.1–9.0) or
yield between the control or AD groups (p > 0.05, ANOVA), or between the
Caucasian and African American groups; note the higher general expression
for miRNA-9, miRNA-34a, miRNA-125b, miRNA-146a and miRNA-155 (a) for
all AD cases over controls and (b) for AD-2 versus AD-1; miRNAs in all AD
cases were compared to 2 unchanging internal controls miRNA-183 and 5S
RNA in the same brain sample; the numbers “1,” “2” and “3” are from
individual control or AD cases; the letter “P” (also analyzed in B); using
miRNA arrays, in Caucasian Americans miRNA-9, miRNA-34a, miRNA-125b,
miRNA-146a and miRNA-155 were found to be up-regulated an average of
1.5-to-3.5 fold over age-matched controls, in African Americans this same
group of miRNAs averaged an up-regulation of 3-to-5-fold over age-matched
controls. (B) (bar graph) depicts quantitative results using RT-PCR, comparing
AD-1 miRNA abundance [AD, (N = 8) relative to control miRNA (N = 8)
signals; Caucasian Americans, set to 1.0 (for ease of comparison; dashed
horizontal line)] to AD-2 miRNA abundance [AD (N = 8) relative to control
miRNA (N = 8) signals; African Americans]; the data is suggestive of
significantly higher miRNA abundance for these 5 potentially pathogenic
miRNAs in the AD-2 group which may, in part, form a molecular-genetic basis
for the predisposition of African Americans, and perhaps other ethnic groups,
to different incidences of AD-type neuropathology, including variations in
dementia development, severity, age of onset, progression, course and
epidemiology (Espino and Lewis, 1998; Tang et al., 1998; Shadlen et al., 1999;
Cui et al., 2010; Venketasubramanian et al., 2010; Reitz et al., 2013; this
paper); ∗p < 0.01; ∗∗p < 0.05 (ANOVA). As further discussed in the text,
selective differences in miRNA abundance may be useful in AD diagnosis and
individualistic therapeutic strategies, to tailor more effective clinical treatment
for AD and other progressive, age-related neurological disorders of the
human CNS.
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